Huntington’s disease (HD) is a progressive, inherited neurodegenerative disorder characterized by involuntary movements, cognitive decline, and psychiatric symptoms. Caused by a mutation in the HTT gene leading to abnormal expansion of CAG repeats, the disease results in toxic accumulation of mutant huntingtin protein that damages neurons—particularly in the striatum and cortex.

The Huntington’s Disease session examines the complex molecular and cellular mechanisms underlying neuronal dysfunction, degeneration, and motor impairment. Researchers explore how disrupted mitochondrial function, protein aggregation, and synaptic dysregulation contribute to the progressive loss of motor and cognitive control.

At the Huntington’s Disease Conference, experts discuss the latest developments in genetic testing, biomarkers, and disease-modifying therapeutic trials. Cutting-edge approaches include antisense oligonucleotides (ASOs), CRISPR-based gene editing, and RNA interference aimed at silencing mutant huntingtin expression.

This session brings together neurologists, neurogeneticists, psychiatrists, and neuroscientists striving to translate laboratory discoveries into effective clinical treatments. Discussions also cover the psychosocial impact on families, genetic counseling, and the importance of multidisciplinary rehabilitation.

Ongoing advances in Neurogenetics and translational neuroscience are providing hope for slowing or preventing disease progression, offering insights applicable to a range of hereditary brain disorders.